{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:13:07Z","timestamp":1794507187963,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.lanepe.2021.100266","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T05:03:54Z","timestamp":1637557434000},"page":"100266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"special_numbering":"C","title":["Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9066-8044","authenticated-orcid":false,"given":"Linda","family":"Davidson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juul M.P.A.","family":"van den Reek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariolina","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron M.C.","family":"Herings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Matzaraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collins K.","family":"Boahen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans M.M.","family":"Groenewoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"van de Veerdonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai G.","family":"Netea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke M.G.J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart Jan","family":"Kullberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10217","key":"10.1016\/j.lanepe.2021.100266_bib0001","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2021.100266_bib0002","article-title":"Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study","author":"Deodhar","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.lanepe.2021.100266_bib0003","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/bjd.18331","article-title":"Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2.5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial","volume":"182","author":"Gottlieb","year":"2020","journal-title":"Br J Dermatol"},{"issue":"10235","key":"10.1016\/j.lanepe.2021.100266_bib0004","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lanepe.2021.100266_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.lanepe.2021.100266_bib0006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546634.2019.1587146","article-title":"Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial","volume":"31","author":"Blauvelt","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.lanepe.2021.100266_bib0007","article-title":"Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)","author":"Bagel","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.lanepe.2021.100266_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001149","article-title":"Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naive active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials","volume":"6","author":"Helliwell","year":"2020","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.lanepe.2021.100266_bib0009","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1007\/s10067-019-04608-z","article-title":"Meta-analysis of IL-17 inhibitors in two populations of rheumatoid arthritis patients: biologic-naive or tumor necrosis factor inhibitor inadequate responders","volume":"38","author":"Wu","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.lanepe.2021.100266_bib0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nrmicro1815","article-title":"An integrated model of the recognition of Candida albicans by the innate immune system","volume":"6","author":"Netea","year":"2008","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"10.1016\/j.lanepe.2021.100266_bib0011","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri3897","article-title":"Immune defence against Candida fungal infections","volume":"15","author":"Netea","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"6025","key":"10.1016\/j.lanepe.2021.100266_bib0012","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.lanepe.2021.100266_bib0013","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1100102","article-title":"STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis","volume":"365","author":"van de Veerdonk","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.lanepe.2021.100266_bib0014","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1038\/cti.2016.71","article-title":"Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity","volume":"5","author":"Okada","year":"2016","journal-title":"Clin Transl Immunology"},{"issue":"1","key":"10.1016\/j.lanepe.2021.100266_bib0015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"10.1016\/j.lanepe.2021.100266_bib0016","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lanepe.2021.100266_bib0017","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.lanepe.2021.100266_bib0018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.lanepe.2021.100266_bib0019","first-page":"2102","article-title":"Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"10273","key":"10.1016\/j.lanepe.2021.100266_bib0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lanepe.2021.100266_bib0021","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR Database System: Basic Facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Information Journal"},{"key":"10.1016\/j.lanepe.2021.100266_bib0022","unstructured":"World Health Organization. Uppsala Monitoring Center, Vigibase\u00ae 2019 [Available from: https:\/\/www.who-umc.org\/"},{"key":"10.1016\/j.lanepe.2021.100266_bib0023","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA). 2019 [Available from: https:\/\/www.meddra.org\/."},{"key":"10.1016\/j.lanepe.2021.100266_bib0024","unstructured":"World Health Organization, WHODrug Global. 2019 [Available from: https:\/\/www.who-umc.org\/whodrug\/whodrug-portfolio\/whodrug-global\/."},{"key":"10.1016\/j.lanepe.2021.100266_bib0025","unstructured":"European Medicines Agency. 2019 [Available from: https:\/\/www.ema.europa.eu\/en."},{"key":"10.1016\/j.lanepe.2021.100266_bib0026","unstructured":"PHARMO Database Network. 2019 [Available from: https:\/\/www.pharmo.nl\/."},{"issue":"5","key":"10.1016\/j.lanepe.2021.100266_bib0027","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/bjd.13087","article-title":"Happy' drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network","volume":"171","author":"van den Reek","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.lanepe.2021.100266_bib0028","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-1-61779-539-8_18","article-title":"Phagocytosis and intracellular killing of Candida albicans by murine polymorphonuclear neutrophils","volume":"845","author":"Vonk","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.lanepe.2021.100266_bib0029","unstructured":"Olink. Validation document inflammation panel 2019 [Available from: www.olink.com\/downloads."},{"issue":"1","key":"10.1016\/j.lanepe.2021.100266_bib0030","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Noren","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"8","key":"10.1016\/j.lanepe.2021.100266_bib0031","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.lanepe.2021.100266_bib0032","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjd.15015","article-title":"Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management","volume":"177","author":"Saunte","year":"2017","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.lanepe.2021.100266_bib0033","doi-asserted-by":"crossref","first-page":"F779","DOI":"10.1152\/ajprenal.00198.2009","article-title":"IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1\/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta","volume":"298","author":"Iyoda","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.lanepe.2021.100266_bib0034","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1034\/j.1399-302X.1999.140606.x","article-title":"Candida albicans triggers interleukin-6 and interleukin-8 responses by oral fibroblasts in vitro","volume":"14","author":"Dongari-Bagtzoglou","year":"1999","journal-title":"Oral Microbiol Immunol"},{"issue":"4","key":"10.1016\/j.lanepe.2021.100266_bib0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0882-4010(03)00004-4","article-title":"Candida albicans triggers interleukin-8 secretion by oral epithelial cells","volume":"34","author":"Dongari-Bagtzoglou","year":"2003","journal-title":"Microb Pathog"},{"issue":"5","key":"10.1016\/j.lanepe.2021.100266_bib0036","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/1521-4141(200205)32:5<1455::AID-IMMU1455>3.0.CO;2-C","article-title":"CD40\/CD40 ligand interactions in the host defense against disseminated Candida albicans infection: the role of macrophage-derived nitric oxide","volume":"32","author":"Netea","year":"2002","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.lanepe.2021.100266_bib0037","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1189\/jlb.0103024","article-title":"Many chemokines including CCL20\/MIP-3alpha display antimicrobial activity","volume":"74","author":"Yang","year":"2003","journal-title":"J Leukoc Biol"},{"issue":"6","key":"10.1016\/j.lanepe.2021.100266_bib0038","doi-asserted-by":"crossref","first-page":"12958","DOI":"10.3390\/ijms160612958","article-title":"Chemokine-derived peptides: novel antimicrobial and antineoplasic agents","volume":"16","author":"Valdivia-Silva","year":"2015","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.lanepe.2021.100266_bib0039","doi-asserted-by":"crossref","first-page":"623","DOI":"10.4049\/jimmunol.167.2.623","article-title":"Cutting edge: IFN-inducible ELR- CXC chemokines display defensin-like antimicrobial activity","volume":"167","author":"Cole","year":"2001","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.lanepe.2021.100266_bib0040","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.exer.2009.12.001","article-title":"Proinflammatory chemokines during Candida albicans keratitis","volume":"90","author":"Yuan","year":"2010","journal-title":"Exp Eye Res"},{"issue":"11","key":"10.1016\/j.lanepe.2021.100266_bib0041","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1007\/s00018-015-1858-6","article-title":"Mononuclear phagocyte-mediated antifungal immunity: the role of chemotactic receptors and ligands","volume":"72","author":"Swamydas","year":"2015","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.lanepe.2021.100266_bib0042","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/ijp.ijp_1178_20","article-title":"Candidiasis in patients treated with interleukin-17 inhibitors","volume":"53","author":"Baez-Gutierrez","year":"2021","journal-title":"Indian J Pharmacol"},{"issue":"7","key":"10.1016\/j.lanepe.2021.100266_bib0043","doi-asserted-by":"crossref","first-page":"648","DOI":"10.2340\/00015555-2900","article-title":"Initial results of secukinumab drug survival in patients with psoriasis: a multicentre daily practice cohort study","volume":"98","author":"van den Reek","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.lanepe.2021.100266_bib0044","article-title":"Secukinumab treatment in psoriasis: a single center experience","author":"Esra A\u011fao\u011flu","year":"2021","journal-title":"Turkderm"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776221002520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776221002520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:48:05Z","timestamp":1763009285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776221002520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":44,"alternative-id":["S2666776221002520"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2021.100266","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741418367.793592557","asserted-by":"object"}]},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2021.100266","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100266"}}